首页> 美国卫生研究院文献>International Journal of Clinical and Experimental Pathology >An immunohistochemical study of primary signet-ring cell carcinoma of the stomach and colorectum: II. expression of MUC1 MUC2 MUC5AC and MUC6 in normal mucosa and in 42 cases
【2h】

An immunohistochemical study of primary signet-ring cell carcinoma of the stomach and colorectum: II. expression of MUC1 MUC2 MUC5AC and MUC6 in normal mucosa and in 42 cases

机译:胃和结直肠原发性印戒细胞癌的免疫组织化学研究:II。正常黏膜和42例MUC1MUC2MUC5AC和MUC6的表达

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Expression of MUC apomucins has rarely been investigated in the signet-ring cell carcinoma (SRCC) of the stomach and colorectum. The author examined immunohistochemically the expression status of MUC1, MUC2, MUC5AC, and MUC6 in 30 cases of gastric SRCC and 12 cases of colorectal SRCC. The normal distribution of these MUC apomucins was also examined in the non-tumorous parts of the stomach and colorectum. In normal tissues, the stomach epithelial cells consistently expressed MUC2, MUC5AC, MUC6, but consistently not MUC1. In colorectum, cryptal epithelial cells consistently expressed MUC2, but consistently not MUC1, MUC5AC, and MUC6. The expression pattern of the gastric SRCC was as follows: MUC1, 3/30 (10%); MUC2, 4/30 (13%); MUC5AC, 20/30 (67%), and MUC6 21/30 (70%). The expression pattern of the colorectal SRCC was as follows: MUC1, 5/12 (42%); MUC2, 11/12 (92%); MUC5AC, 4/12 (33%); and MUC6, 0/12 (0%). Significant differences (p<0.05) were found in the expression of MUC1 (stomach SRCC 10% vs colorectal SRCC 42%), MUC2 (13% vs 92%), MUC5AC (67% vs 33%), and MUC6 (70% vs 0%). Thus, there was a significant tendency that primary gastric SRCC express MUC5AC and MUC6 but not MUC1 and MUC2, while primary colorectal SRCC express MUC1, MUC2 and MUC5A, but not MUC6. These different expressions of these MUC apomucins in gastric and colorectal SRCC seem useful to determine the primary site of metastatic SRCC and for differential diagnosis of SRCC of other sites. In the gastric SRCC, the up-regulation of MUC1 and the down-regulation of MUC2, MUC5AC and MUC6 appear to be associated with carcinogenesis, malignant potential, progression, and clinical behaviors in gastric SRCC. In the colorectal SRCC, the up-regulation of MUC1 and MUC5AC may be associated with carcinogenesis, malignant potential, progression, and clinical behaviors in colorectal SRCC. A comparative review of the present SRCC and presently reported ordinary adenocarcinoma and SRCC cases of the stomach and colorectum was performed.
机译:在胃和结肠直肠的印戒细胞癌(SRCC)中,很少研究MUC载脂蛋白的表达。作者采用免疫组织化学方法检测了30例胃SRCC和12例结直肠SRCC中MUC1,MUC2,MUC5AC和MUC6的表达状态。还检查了这些MUC载脂蛋白的正态分布在胃和结肠直肠的非肿瘤部位。在正常组织中,胃上皮细胞始终表达MUC2,MUC5AC,MUC6,但始终不表达MUC1。在结直肠中,隐性上皮细胞始终表达MUC2,但始终不表达MUC1,MUC5AC和MUC6。胃SRCC的表达模式如下:MUC1,3 / 30(10%);和。 MUC2,4 / 30(13%); MUC5AC 20/30(67%)和MUC6 21/30(70%)。大肠SRCC的表达模式如下:MUC1,5 / 12(42%)。 MUC2,11 / 12(92%); MUC5AC,4/12(33%);和MUC6,0 / 12(0%)。在MUC1(胃SRCC为10%对结直肠SRCC为42%),MUC2(13%对92%),MUC5AC(67%对33%)和MUC6(70%对70%)的表达中发现了显着差异(p <0.05) 0%)。因此,存在明显的趋势,即原发性胃SRCC表达MUC5AC和MUC6而不表达MUC1和MUC2,而原发性大肠SRCC表达MUC1,MUC2和MUC5A而不表达MUC6。这些MUC载脂蛋白在胃和大肠SRCC中的这些不同表达似乎对确定转移性SRCC的主要部位和对其他部位的SRCC的鉴别诊断很有用。在胃SRCC中,MUC1的上调和MUC2,MUC5AC和MUC6的下调似乎与胃SRCC的致癌性,恶性潜能,进展和临床行为有关。在大肠SRCC中,MUC1和MUC5AC的上调可能与大肠SRCC中的癌变,恶性潜能,进展和临床行为有关。对目前的SRCC和目前报道的普通腺癌以及胃和结直肠的SRCC病例进行了比较审查。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号